| 2025-11-12 |
详情>>
股本变动：
变动后总股本6325.85万股
变动原因 ▼▲
- 原因：
- From June 30, 2025 to September 30, 2025
Stock plan related activity
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.96美元,归母净利润-6046.5万美元,同比去年增长-17.31%
|
| 2025-08-19 |
详情>>
内部人交易：
HEIDEN WILLIAM K共交易2笔
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-1.23美元,归母净利润-7728.7万美元,同比去年增长28.34%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.65美元,归母净利润-4103.6万美元,同比去年增长21.37%
|
| 2025-05-13 |
财报披露：
美东时间 2025-05-13 盘后发布财报
|
| 2025-04-11 |
股东大会：
将于2025-05-21召开股东大会
会议内容 ▼▲
- 1.To elect four Class III directors listed in the attached proxy materials to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected and qualified or until their earlier death, resignation or removal;
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025;
3.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the attached proxy statement;
4.To approve an amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan to increase the number of shares of our common stock available for issuance thereunder by 1,250,000 shares;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-03-20 |
详情>>
业绩披露：
2022年年报每股收益-1.95美元,归母净利润-1.2亿美元,同比去年增长40.75%
|
| 2025-03-20 |
详情>>
业绩披露：
2024年年报每股收益-1.07美元,归母净利润-6696.6万美元,同比去年增长-639.3%
|
| 2024-11-05 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.82美元,归母净利润-5154.5万美元,同比去年增长-239.26%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益-1.73美元,归母净利润-1.08亿美元,同比去年增长-654.23%
|
| 2024-08-06 |
详情>>
业绩披露：
2023年中报每股收益0.31美元,归母净利润1946.00万美元,同比去年增长118.06%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.84美元,归母净利润-5219万美元,同比去年增长-37.31%
|
| 2024-04-08 |
股东大会：
将于2024-05-21召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors listed in the attached proxy materials to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected and qualified or until their earlier death, resignation or removal;
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024;
3.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the attached proxy statement;
4.To approve an amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan to increase the number of shares of our common stock available for issuance thereunder by 2,000,000 shares;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-03-07 |
详情>>
业绩披露：
2023年年报每股收益-0.15美元,归母净利润-905.8万美元,同比去年增长92.44%
|
| 2023-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.60美元,归母净利润3701.40万美元,同比去年增长127.92%
|
| 2023-08-10 |
复牌提示：
2023-08-10 09:32:56 停牌，复牌日期 2023-08-10 09:37:56
|
| 2023-04-17 |
股东大会：
将于2023-05-31召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors listed in the attached proxy materials to hold office until the 2026 Annual Meeting of Stockholders or until their successors are elected and qualified or until their earlier death, resignation or removal;
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023;
3.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the attached proxy statement;
4.To approve the MacroGenics, Inc. 2023 Equity Incentive Plan;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-04-08 |
股东大会：
将于2022-05-19召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors listed in the attached proxy materials to hold office until the 2025 Annual Meeting of Stockholders or until their successors are elected and qualified or until their earlier death, resignation or removal;
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022;
3.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the attached proxy statement;
4.To approve, on advisory basis, the frequency of future advisory votes on executive compensation;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-02 |
股东大会：
将于2021-05-13召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors listed in the attached proxy materials to hold office until the 2024 Annual Meeting of Stockholders or until their successors are elected and qualified or until their earlier death, resignation or removal;
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021;
3.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the attached proxy statement;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-04-03 |
股东大会：
将于2020-05-14召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors listed in the attached proxy materials to hold office until the 2023 Annual Meeting of Stockholders or until their successors are elected and qualified or until their earlier death, resignation or removal;
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020;
3.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the attached proxy statement;
4.To approve our stock option exchange program as described in the attached proxy statement;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-04-05 |
股东大会：
将于2019-05-16召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors listed in these proxy materials to hold office until the 2022 Annual Meeting of Stockholders or until their successors are elected and qualified or until their earlier death, resignation or removal;
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019;
3.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in these proxy materials;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2018-04-06 |
股东大会：
将于2018-05-17召开股东大会
会议内容 ▼▲
- 1. To elect three Class II directors listed in these proxy materials to hold office until the 2021 Annual Meeting of Stockholders or until their successors are elected and qualified or until their earlier death, resignation or removal;
2. To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018;
3. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in these proxy materials;
4. To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2017-04-04 |
股东大会：
将于2017-05-18召开股东大会
会议内容 ▼▲
- 1. To elect two Class I directors listed in these proxy materials to hold office until the 2020 Annual Meeting of Stockholders or until their successors are elected and qualified or until their earlier death, resignation or removal;
2. To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017;
3. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in these proxy materials;
4. To approve the 2016 Employee Stock Purchase Plan;
5. To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2016-04-07 |
股东大会：
将于2016-05-18召开股东大会
会议内容 ▼▲
- 1. To elect two Class III directors listed in these proxy materials to hold office until the 2019 Annual Meeting of Stockholders or until their successors are elected.
2. To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2016.
3. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in these proxy materials.
4. To approve, on an advisory basis, the frequency of future advisory votes on executive compensation.
5. To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|